NOD2 Antibody | Affinity Biosciences

Product:	NOD2 Antibody
Catalog:	DF12125
Description:	Rabbit polyclonal antibody to NOD2
Application:	WB IHC IF/ICC
Cited expt.:	WB, IHC
Reactivity:	Human, Mouse, Rat
Prediction:	Pig, Bovine, Horse, Sheep, Rabbit
Mol.Wt.:	100-110 kDa; 115kD(Calculated).
Uniprot:	Q9HC29
RRID:	AB_2844930

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
100ul	$280	In stock
200ul	$350	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MS Report

HPLC Report

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human,Mouse,Rat

Prediction:

Pig(92%), Bovine(100%), Horse(92%), Sheep(100%), Rabbit(92%)

Clonality:

Polyclonal

Specificity:

NOD2 Antibody detects endogenous levels of total NOD2.

RRID:

AB_2844930
Cite Format: Affinity Biosciences Cat# DF12125, RRID:AB_2844930.

Conjugate:

Unconjugated.

Purification:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

Storage:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

ACUG; Arthrocutaneouveal granulomatosis; BLAU; CARD15; Caspase recruitment domain family, member 15; Caspase recruitment domain protein 15; Caspase recruitment domain-containing protein 15; CD; CLR16.3; IBD1; Inflammatory bowel disease protein 1; LRR containing protein; NLR family, CARD domain containing 2; NLRC2; NOD like receptor C2; NOD2; NOD2 protein; NOD2_HUMAN; NOD2B; nucleotide binding oligomerization domain 2; Nucleotide binding oligomerization domain containing 2; Nucleotide binding oligomerization domain, leucine rich repeat and CARD domain containing 2; Nucleotide-binding oligomerization domain-containing protein 2; PSORAS1;

Immunogens

Immunogen:

A synthesized peptide derived from human NOD2, corresponding to a region within N-terminal amino acids.

Uniprot:

Q9HC29(NOD2_HUMAN) >>Visit HPA database.

Gene(ID):

NOD2(64127)

Expression:

Q9HC29 NOD2_HUMAN:

Expressed in intestinal mucosa, mainly in Paneth cells and, at lower extent, in the glandular epithelium.

Sequence:

Q9HC29 NOD2_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQPLSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERGFVSQYECDEIRLPIFTPSQRARRLLDLATVKANGLAAFLLQHVQELPVPLALPLEAATCKKYMAKLRTTVSAQSRFLSTYDGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQDFQEFLFVFPFSCRQLQCMAKPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDPTSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRLIRLLQETSALHGLCHLPVFSWMVSKCHQELLLQEGGSPKTTTDMYLLILQHFLLHATPPDSASQGLGPSLLRGRLPTLLHLGRLALWGLGMCCYVFSAQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFQCFFAAFYLALSADVPPALLRHLFNCGRPGNSPMARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFHSIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFCSVGPTECAALAFVLQHLRRPVALQLDYNSVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLTDGCAHSMAKLLACRQNFLALRLGNNYITAAGAQVLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEELCLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Bovine

100

Sheep

100

Pig

Horse

Rabbit

Dog

Xenopus

Zebrafish

Chicken

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Q9HC29_NOD2_HUMAN

Function:

Involved in gastrointestinal immunity. Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3, INAVA and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response. Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages. Component of an autophagy-mediated antibacterial pathway together with ATG16L1. Plays also a role in sensing single-stranded RNA (ssRNA) from viruses. Interacts with mitochondrial antiviral signaling/MAVS, leading to activation of interferon regulatory factor-3/IRF3 and expression of type I interferon.

PTMs:

Polyubiquitinated following MDP stimulation, leading to proteasome-mediated degradation.

Subcellular Location:

Cytoplasm. Membrane. Mitochondrion. Basolateral cell membrane.

Tissue Specificity:

Expressed in intestinal mucosa, mainly in Paneth cells and, at lower extent, in the glandular epithelium.

Family&Domains:

The ATG16L1-binding motif mediates interaction with ATG16L1.

Intramolecular interactions between the N-terminal moiety and the leucine-rich repeats (LRR) may be important for autoinhibition in the absence of activating signal. In the absence of LRRs, the protein becomes a constitutive activator of CASP1 cleavage and proIL1B processing.

Research Fields

· Environmental Information Processing > Signal transduction > TNF signaling pathway. (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Shigellosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Organismal Systems > Immune system > NOD-like receptor signaling pathway. (View pathway)

References

1). Elevated muramyl dipeptide by sialic acid-facilitated postantibiotic pathobiont expansion contributes to gut dysbiosis-induced mastitis in mice. Journal of advanced research, 2024 (PubMed: 39374734) [IF=11.4]

Application: WB Species: Mouse Sample:

Fig. 5. Enterococcus aggravates gut dysbiosis-induced mastitis through activating NOD2 by MDP production. (A-D) Representative western blot images of NOD2 and NK-κB signaling in the mammary glands from the indicated mice and relative intensity analysis (n = 3). (E and F) Serum MDP concentrations in sialic acid- and E. cecorum-treated mice. (G and H) Mice at E14 were treated with MDP every other day intraperitoneally 10 times until PND14. (G) Representative H&E-stained images of mammary glands and histological analysis. (H) Mammary TNF-α and IL-1β levels and MPO activity were detected in the indicated mice (n = 5). Data are expressed as mean ± SD. *p < 0.05, **p < 0.01 and ***p < 0.001 by one-way ANOVA followed by Tukey’s test (E-G) and two-tailed unpaired Student’s t test (B and D-H). ns, no significance. Scale bars, 50 μm.

2). Cytosolic HMGB1 Mediates LPS-Induced Autophagy in Microglia by Interacting with NOD2 and Suppresses Its Proinflammatory Function. Cells, 2022 (PubMed: 35954253) [IF=6.0]

3). Novel chimeric TLR2/NOD2 agonist CL429 exhibited significant radioprotective effects in mice. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021 (PubMed: 33609010) [IF=5.3]

Application: WB Species: mice Sample: intestinal tissues

FIGURE 5 The mechanism for the radioprotective effect of CL429. (A) C57BL/6 mice and TLR2 KO mice were treated with CL429 before TBI, and then, the survival was monitored (WT n = 11, TLR2 KO n = 7). (B) The representative pathological images of haematopoietic system and gastrointestinal tract at 3.5 d after radiation. (C) The protein expression of TLR2 and NOD2 after siRNA knockdown. Cell viability was determined using CCK-8 at 24 h after radiation. *P < .05 vs IR groups. (D) The effects of CL429 on TLR2, NOD2, MyD88 and p-IKK at 0 h, 2 h, 4 h, 8 h, 12 h and 24 h were measured by Western blot assay. (E) IL-6, IL-11, IL-12 and TNF-α were detected by ELISA 24 h after radiation. *P < .05, **P < .01 vs IR + PBS groups

4). Interferon-γ activated T-cell IRGM–autophagy axis in oral lichen planus. International Immunopharmacology, 2021 (PubMed: 33639564) [IF=4.8]

Application: WB Species: Human Sample: peripheral blood T cells

Fig. 3. Upregulated expression of IRGM and autophagy in peripheral blood T cells of OLP patients. (A-B) Quantitative real-time RT-PCR results showed that IRGM mRNA levels increased in the peripheral blood T cells of OLP (n = 22, P = 0.001), non-erosive OLP (NEOLP, n = 12, P = 0.013) and erosive OLP (EOLP, n = 10, P = 0.033) when compared with that in healthy controls (n = 15), respectively. However, the relative levels of IRGM mRNA showed no significant difference between different clinical types of OLP (P > 0.05). (C-D) Similarly, the relative protein level of IRGM increased in peripheral blood T cells of EOLP (P < 0.001) and NEOLP (P < 0.001) when compared with that in healthy controls. (E-G) Meanwhile, the relative protein level of LC3B upregulated, whereas SQSTM1 and NOD2 protein expression decreased in peripheral blood T cells of all OLP patients (P < 0.05). There were significant differences of expression of LC3B (E, P < 0.001) and SQSTM1 protein (F, P < 0.001) between EOLP and NEOLP groups. The assay was performed in triplicate no less than 3 times. Data were shown as mean ± SEM. * P < 0.05, ** P < 0.01, ***P < 0.001, NS: P > 0.05, nonsignificantly.

5). Analyses of Transcriptomics upon IL-1β-Stimulated Mouse Chondrocytes and the Protective Effect of Catalpol through the NOD2/NF-κB/MAPK Signaling Pathway. Molecules (Basel, Switzerland), 2023 (PubMed: 36838594) [IF=4.6]

Application: WB Species: Mouse Sample:

Figure 7 The effects of catalpol on the levels of NOD2, IKBα, and P65. (A) NOD2 mRNA level (n = 6); (B) NDD2 protein level; (C) IKBα protein level; (D) P65 protein level (B–D n = 3); above, densitometric analysis; below, (E) representative images of immunoblots. The data are the mean ± S.D. of the mean. * p < 0.05 vs. normal group (N); ** p < 0.01 vs. normal group (N); # p < 0.05 vs. IL-1β group; ## p < 0.01 vs. IL-1β group.

6). An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma. Frontiers in Oncology, 2021 (PubMed: 33828988) [IF=3.5]

Application: IHC Species: Human Sample: HCC Tissues and Adjacent Non-Tumorous Tissues

Figure 10 Experiment confirmed the difference of the prognostic gene expression between HCC and adjacent non-tumor tissues. (A) The mRNA expression analysis by qRT-RCR. (B) The protein expression analysis by IHC.

7). Astaxanthin Alleviates Inflammatory Response in Neonatal Necrotizing Enterocolitis Rats by Regulating NOD2/TLR4 Pathway. Gastroenterology research and practice, 2023 (PubMed: 37021078) [IF=2.0]

Application: WB Species: Rat Sample:

Figure 4. Astaxanthin inhibited the inflammatory- and apoptosis-related proteins of intestinal tissues in NEC rats. (a, b, c, and d) Western blot was used to test the expressions of TNF-α, inducible nitric oxide synthase (iNOS), nuclear factor-κB (NF-κB), BAX, Bcl-2, toll-like receptor 4 (TLR4), and nucleotide-binding oligomerization domain 2 (NOD2) of intestinal tissues in rats, n = 3 in each group; ▲P < 0.05, ▲▲P < 0.01 vs. control group. ★P < 0.05, ★★P < 0.01 vs. NEC group.

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

NOD2 Antibody - #DF12125